1. Red-hot biotechs to take spotlight at ASH virtual meeting — Moderna's 3-month data raise hopes for COVID-19 vaccine durability — BioNTech founder vaults into world's 500 richest — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

At key meeting, FDA advisors debate if early coronavirus vaccine approvals may compromise...

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Oct 23, 2020 at 11:02 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Nov 21, 2001
    Likes Received:
    via Coronavirus vaccine studies run by Pfizer and Moderna are expected to soon deliver results that show whether or not the experimental shots truly work. If data are positive, the companies will likely ask the Food and Drug Administration for emergency clearance.

    Such an early approval, should one be granted, would be a turning point in a pandemic that looks far from over. But an emergency use authorization, or EUA, could also raise thorny questions about how the companies complete their trials, and might complicate studies of other vaccines.

    article source